Adrucil®
Fluorouracil is a pyrimidine analog and antimetabolite that inhibits thymidylate synthase. A cornerstone of GI cancer treatment for decades.
| Dosage Form | IV Injectable (Solution) |
| Strength | 50 mg/mL; 500 mg, 1000 mg, 2500 mg, 5000 mg vials |
| Storage | Store at 15–30°C. Protect from light. Do not refrigerate. |
| Category | Oncology |
| Availability | Available for Transfer |
Colorectal cancer; breast cancer; gastric cancer; pancreatic cancer. Often combined with leucovorin and/or oxaliplatin (FOLFOX).
Converted intracellularly to active metabolites that inhibit thymidylate synthase and are incorporated into RNA and DNA, disrupting nucleic acid synthesis.
Each Burrard Pharmaceuticals technology transfer package for Fluorouracil (5-FU) includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.